Brexanolone is under clinical development by Seaport Therapeutics and currently in Phase II for Major Depressive Disorder. According to GlobalData, Phase II drugs for Major Depressive Disorder have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Brexanolone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Brexanolone overview

Brexanolone is under development for the treatment of neurological and neuropsychological conditions, including major depression disorder (MDD) with anxiety, sleep disorders, fragile X tremor-associated syndrome, essential tremor, epileptic disorders, postpartum depression, among others. It is administered by oral route. It acts by targeting GABAA receptor. The drug candidate is developed based on Glyph technology.

Seaport Therapeutics overview

Seaport Therapeutics, a subsidiary of Puretech Health Plc, is a clinical stage company engaged in research and development of novel therapeutics for the treatment of central nervous system related diseases. The company is headquartered in Boston, Massachusetts, the US.

For a complete picture of Brexanolone’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.